Treatment of Squamous Cell Carcinoma With Intralesional 5-Fluorouracil

Morse, Lisa; Kendrick, Christina G; Hooper, Deirdre; Ward, Holly; Parry, Edward L.

doi:10.1046/j.1524-4725.2003.29355.x

Cited by 22 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[11][12][13][14][15][16][17][18][19] Three articles reported the use of 5FU in 23 BCCs. 12,20,21 Table II summarizes the data from these 12 studies.…”

Section: -Fluorouracilmentioning

confidence: 99%

See 1 more Smart Citation

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…[11][12][13][14][15][16][17][18][19] Three articles reported the use of 5FU in 23 BCCs. 12,20,21 Table II summarizes the data from these 12 studies.…”

Section: -Fluorouracilmentioning

confidence: 99%

“…Posttreatment biopsies were done in 4 patients. [16][17][18] Some cases have been followed up for as long as 24 months or more without recurrence. 12 Laboratory testing (Table V) was done in 6 patients without any abnormal finding.…”

Section: -Fluorouracilmentioning

confidence: 99%

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…A case report of intralesional 5-FU reported no recurrence 5 months after treatment. 644 One series of 33 patients with 53 SCCs reported complete post-treatment regression of tumour in 42 SCCs (79%) treated with up to three courses of 5%, 10% or 20% topical 5-FU, of which 27 (64%) were confirmed histologically. 646 The remaining SCCs regressed partially (15%) or progressed (6%).…”

Section: -Fluorouracilmentioning

confidence: 99%

“…We found four studies in which single-agent 5-FU was used to treat eligible SCCs, two of which related to intralesional treatment 643,644 and two to topical administration of 5-FU 645,646 (Table 55). …”

Section: -Fluorouracilmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

“…In 1 Fall be richt konn te durch eine in tra lä sio na le Ap pli kati on von 5-FU über 8 Wo chen mit Do sen von 0,8-2,4 ml eine his to lo gisch be stä tigte kom plet te Re mis si on des Tu mors fest gestellt wer den [23]. In ei ner an de ren Stu die mit 23 Pa ti en ten kam es nach in tra tu mora ler Ap pli ka ti on von 5-FU/Epi ne phri neGel nach 4-6 Wo chen The ra pie in 96 zu ei ner bi op tisch ge si cher ten Tu mor re mis sion bei gu tem kos me ti schen Er geb nis [14].…”

Section: -Fuunclassified

Therapieoptionen bei epithelialen Hauttumoren

2005

View full text Add to dashboard Cite

There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected. The risk factors are identified. The choice of the appropriate treatment for each individual is crucial. Major consideration include high cure rate, low long-term recurrence rate and few side effects. In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.

show abstract

Treatment of Squamous Cell Carcinoma With Intralesional 5-Fluorouracil

Abstract: This modality may provide patients with SCC in cosmetically important locations or in areas that require complex surgery the advantage of a nonsurgical cure.

Cited by 22 publications

References 17 publications

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Therapieoptionen bei epithelialen Hauttumoren

Contact Info

Product

Resources

About